Recent Updates — ALEC
Alector priced an underwritten public offering of 36,600,000 shares of common stock at $2.05 per share. The transaction is expected to generate gross proceeds of approximately $75 million before deducting underwriting discounts and other offering expenses. All shares are being sold by the company, with Morgan Stanley & Co. LLC and BTIG, LLC serving as joint lead book-running managers. The offering includes participation from new and existing investors such as TCGX, BVF Partners, ADAR1 Capital Management, and Deep Track Capital. Closing is expected on October 19, 2026, subject to customary conditions. Alector is a biotechnology company focused on developing therapies for neurodegenerative diseases.
The Board of Directors approved an option repricing for approximately 4.05 million underwater stock options held by continuing employees, lowering the exercise price from a range of $6.48 to $33.11 down to $1.87 per share. The new rate matches the closing stock price on October 13, 2026. To ensure retention, employees exercising these repriced options before the end of a one-year Retention Period must pay a premium equal to their original exercise price. This action aims to motivate key personnel without incurring additional dilution from new grants or cash expenditures. Alector is a biotechnology company focused on developing therapies for neurodegenerative diseases.
Alector granted Genentech exclusive worldwide rights to develop and commercialize its AL050 program, a brain-penetrant engineered glucocerebrosidase enzyme replacement therapy. Alector will receive a $100 million upfront payment and is eligible for up to $1.17 billion in development, regulatory, and commercial milestone payments, plus tiered royalties on net sales. Genentech assumes responsibility for all development, manufacturing, and commercialization activities. Concurrently, Alector exercised an option to license certain patents from Spur Therapeutics for a $15 million payment. The transaction is expected to extend Alector's cash runway into 2029. Alector is a biotechnology company focused on developing therapies to counteract neurodegenerative diseases.
Alector, Inc. reported financial results for the quarter ended June 30, 2026, on August 6, 2026. The company generated $3.3 million in collaboration revenue and incurred a net loss of $23.0 million, or $0.21 per share, compared to a net loss of $30.5 million in the prior year period. Research and development expenses decreased to $19.5 million from $27.6 million, while general and administrative expenses fell to $8.3 million from $14.4 million, primarily due to workforce reductions. As of June 30, 2026, Alector held $172.8 million in cash, cash equivalents, and investments, providing sufficient runway through at least 2027. The company also provided updates on its preclinical pipeline, selecting AL137 as the lead anti-amyloid beta antibody candidate for Alzheimer’s disease with an IND submission targeted for Q1 2027.
Alector is a biotechnology company focused on developing therapies to counteract neurodegenerative diseases using its proprietary Alector Brain Carrier platform.
Alector, Inc. announced the termination of its collaboration and license agreement with GSK, effective January 2, 2027, following clinical trial failures for latozinemab and nivisnebart. Additionally, the company repaid in full and terminated its loan and security agreement with Hercules Capital, Inc., paying an aggregate principal amount of $10,428,827.77 plus interest and charges. Alector, Inc. is a biotechnology company focused on developing investigational monoclonal antibodies for neurodegenerative diseases.